Software: all-important, but all too easily overlooked
This article was originally published in Clinica
Badly-written or inadequately-tested software can lead to adverse incidents with medtech products. Yet lack of attention to this issue results in regulators and manufacturers often citing software as a source of problems in real use. In this article, medtech consultant Trevor Lewis gives some much-needed pointers about how to start working towards the "state of the art" demanded by the EU Medical Devices Directive (93/42) and its revised version (2007/47) - which must be fully applied by March 21 2010
You may also be interested in...
Trump Administration’s attempt to eliminate rebates in the US Medicare outpatient drug benefit program is the easiest and most certain item among the 11th hour pricing policy changes for the incoming Biden Administration to undo. But it still had a major impact on the dynamics of the drug pricing debate.
US FDA will simultaneously review the vaccines, with Moderna’s advisory committee set a week after Pfizer’s. ACIP emergency meeting scheduled for 1 December with vote likely on distribution priority for health care personnel.
Sabinsa provided FDA and FTC with documentation of “an ingredient falsely marketed and sold as vitamin C derived from amla fruit (Emblica officinalis), which two independent labs have confirmed is actually derived from corn, sugarcane or other plants.”